Literature DB >> 3668243

Renal haemodynamic studies in obesity hypertension.

E Reisin1, F G Messerli, H O Ventura, E D Frohlich.   

Abstract

Previous investigations have reported the systemic haemodynamic characteristics of obese hypertensive patients; however, their renal haemodynamics have not been explored. This report compares the renal and systemic haemodynamic findings in obese and lean normotensive and hypertensive patients. Our results demonstrate that both normotensive and hypertensive obese subjects had an increased renal blood flow, total blood volume and cardiac output, with decreased total peripheral and renal vascular resistances in comparison with lean normotensive and hypertensive patients. Body weight correlated directly and significantly with total blood volume, cardiac output and renal blood flow but indirectly with total peripheral resistance. Therefore, the elevated cardiac output and volume expansion found in obese patients were associated with increased renal perfusion; this increased renal blood flow accounts for the reduced renal vascular resistance in patients with obesity hypertension. Thus, we suggest that this effect of volume expansion in obesity could counteract the opposing effect of active vasoconstriction produced by the hypertensive disease and may account for the difference in prognosis of obese and lean hypertensive patients.

Entities:  

Mesh:

Year:  1987        PMID: 3668243

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  21 in total

1.  Weight loss: a tool to reduce proteinuria.

Authors:  Zohreh Soltani; Efrain Reisin
Journal:  Curr Hypertens Rep       Date:  2011-04       Impact factor: 5.369

Review 2.  The impacts of obesity on the cardiovascular and renal systems: cascade of events and therapeutic approaches.

Authors:  Zohreh Soltani; Vaughn Washco; Stephen Morse; Efrain Reisin
Journal:  Curr Hypertens Rep       Date:  2015-02       Impact factor: 5.369

3.  Hypertension research program at ochsner: a program in translational research.

Authors:  Edward Frohlich
Journal:  Ochsner J       Date:  2002

4.  Central body fat distribution associates with unfavorable renal hemodynamics independent of body mass index.

Authors:  Arjan J Kwakernaak; Dorien M Zelle; Stephan J L Bakker; Gerjan Navis
Journal:  J Am Soc Nephrol       Date:  2013-04-11       Impact factor: 10.121

5.  Different pathomechanisms of essential and obesity-associated hypertension in adolescents.

Authors:  Akos Baráth; Sándor Túri; Ilona Németh; Csaba Bereczki; Balázs Gellén; Ibolya Haszon; Péter Monostori
Journal:  Pediatr Nephrol       Date:  2006-08-08       Impact factor: 3.714

6.  Correlation of ultrasonographic measurement of intrarenal arterial resistance index with microalbuminuria in nonhypertensive, nondiabetic obese patients.

Authors:  Fang Han; Ningning Hou; Wei Miao; Xiaodong Sun
Journal:  Int Urol Nephrol       Date:  2012-10-09       Impact factor: 2.370

7.  Pharmacokinetics of intravenous levofloxacin administered at 750 milligrams in obese adults.

Authors:  Aaron M Cook; Craig Martin; Val R Adams; R Scott Morehead
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

8.  Obstructive sleep apnea in patients with end-stage lung disease.

Authors:  Ayal Romem; Aldo Iacono; Elizabeth McIlmoyle; Kalpesh P Patel; Robert M Reed; Avelino C Verceles; Steven M Scharf
Journal:  J Clin Sleep Med       Date:  2013-07-15       Impact factor: 4.062

Review 9.  Mechanisms underlying obesity associated with systemic and renal hemodynamics in essential hypertension.

Authors:  Edward D Frohlich; Dinko Susic
Journal:  Curr Hypertens Rep       Date:  2008-04       Impact factor: 5.369

Review 10.  Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis.

Authors:  Vivette D D'Agati; Avry Chagnac; Aiko P J de Vries; Moshe Levi; Esteban Porrini; Michal Herman-Edelstein; Manuel Praga
Journal:  Nat Rev Nephrol       Date:  2016-06-06       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.